Live attenuated seasonal and pandemic influenza vaccine in school-age children: A randomized controlled trial

Vaccine

Volumn 31, Issue 15, 2013, Pages 1937-1943

  Klick, Brendan ^a   Durrani, Sunita ^a   Chan, Kwok Hung ^a   Ip, Dennis K M ^a   Chou, Erica S K ^a   Kwok, Henry K H ^b   Ng, Sophia ^a   Chiu, Susan S ^a   Peiris, J S Malik ^a   Leung, Gabriel M ^a   Cowling, Benjamin J ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Influenza; Pandemic; Vaccine; Vaccine efficacy

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

ACUTE RESPIRATORY FAILURE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; MYALGIA; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHOOL CHILD; SEASONAL INFLUENZA; SORE THROAT; TELECONSULTATION; THROAT CULTURE;

CHILD; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NORTH AMERICA; PANDEMICS; PLACEBOS; RISK; SEASONS; SPECIES SPECIFICITY; VACCINES, ATTENUATED;

EID: 84875253206     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.017     Document Type: Article

References (30)

1. Jefferson T., Rivetti A., Di Pietrantonj C., Demicheli V., Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012, 8:CD004879.
2. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
3. Mallory R.M., Malkin E., Ambrose C.S., Bellamy T., Shi L., Yi T., et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 2010, 5:e13755.
4. Griffin M.R., Monto A.S., Belongia E.A., Treanor J.J., Chen Q., Chen J., et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS ONE 2011, 6:e23085.
5. Valenciano M., Kissling E., Cohen J.-M., Oroszi B., Barret A.-S., Rizzo C., et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2011, 8:e1000388.
6. Andrews N., Waight P., Yung C.F., Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011, 203:32-39.
7. Wichmann O., Stocker P., Poggensee G., Altmann D., Walter D., Hellenbrand W., et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010, 15.
8. Puig-Barbera J., Arnedo-Pena A., Pardo-Serrano F., Tirado-Balaguer M.D., Perez-Vilar S., Silvestre-Silvestre E., et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine 2010, 28:7460-7467.
9. Simpson C.R., Ritchie L.D., Robertson C., Sheikh A., McMenamin J. Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 2010, 14:313-346.
10. Mahmud S., Hammond G., Elliott L., Hilderman T., Kurbis C., Caetano P., et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 2011, 29:7975-7981.
11. Castilla J., Moran J., Martinez-Artola V., Fernandez-Alonso M., Guevara M., Cenoz M.G., et al. Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: cohort and case-control study. Vaccine 2011, 29:5919-5924.
12. Song J.Y., Cheong H.J., Heo J.Y., Noh J.Y., Choi W.S., Park D.W., et al. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 2011, 29:1395-1398.
13. Yin J.K., Chow M.Y., Khandaker G., King C., Richmond P., Heron L., et al. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. Vaccine 2012, 30:3209-3222.
14. Cowling B.J., Chan K.H., Fang V.J., Cheng C.K., Fung R.O., Wai W., et al. Facemasks and hand hygiene to prevent influenza transmission in households: a randomized trial. Ann Intern Med 2009, 151:437-446.
15. Cowling B.J., Chan K.H., Fang V.J., Lau L.L., So H.C., Fung R.O., et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010, 362:2175-2184.
16. Cowling B.J., Ng S., Ma E.S., Cheng C.K., Wai W., Fang V.J., et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2010, 51:1370-1379.
17. Cowling B.J., Ng S., Ma E.S., Fang V.J., So H.C., Wai W., et al. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis 2012, 55:695-702.
18. Chan K.H., Peiris J.S.M., Lim W., Nicholls J.M., Chiu S.S. Comparison of nasopharyngeal flocked swabs and aspirates from pediatric patients for rapid diagnosis of respiratory viruses. J Clin Virol 2008, 42:65-69.
19. Peiris J.S., Tang W.H., Chan K.H., Khong P.L., Guan Y., Lau Y.L., et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003, 9:628-633.
20. Daly L. Simple sas macros for the calculation of exact binomial and Poisson confidence-limits. Comput Biol Med 1992, 22:351-361.
21. Subbiah M., Srinivasan M.R. Classification of 2×2 sparse data sets with zero cells. Stat Probabil Lett 2008, 78:3212-3215.
22. Friedrich J.O., Adhikari N.K., Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007, 7:5.
23. Ambrose C.S., Yi T., Walker R.E., Connor E.M. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008, 27:744-748.
24. Ambrose C.S., Wu X., Belshe R.B. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010, 29:806-811.
25. Wu J.T., Ma E.S., Lee C.K., Chu D.K., Ho P.L., Shen A.L., et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 2010, 51:1184-1191.
26. Hurwitz E.S., Haber M., Chang A., Shope T., Teo S., Ginsberg M., et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000, 284:1677-1682.
27. Loeb M., Russell M.L., Moss L., Fonseca K., Fox J., Earn D.J., et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010, 303:943-950.
28. King J.C., Stoddard J.J., Gaglani M.J., Moore K.A., Magder L., McClure E., et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006, 355:2523-2532.
29. Liao Q., Cowling B.J., Lam W.W., Fielding R. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: a longitudinal study. PLoS ONE 2011, 6:e17713.
30. Piedra P.A., Gaglani M.J., Riggs M., Herschler G., Fewlass C., Watts M., et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005, 116:e397-e407.